Synthesis of *cis*- and *trans*-5,8-Dihydroxy-5,6,7,8-tetrahydro-1,4- naphthoquinone

Shiho Arima,^{*,*a*} Yaeko Yamada (Konda),^{*a*} Kazuyoshi Takeda,^{*b*} Hiroaki Takayanagi,^{*a*} and Yoshihiro Harigaya^{*a*}

School of Pharmaceutical Sciences, Kitasato University,^a 5–9–1 Shirokane, Minato-ku, Tokyo 108–8641, Japan and Center for Advanced Technology, EBARA Research Co., Ltd.,^b 4–2–1 Honfujisawa, Fujisawa 251–8502, Japan. Received March, 23, 2001; accepted June 18, 2001

Cis- and *trans*-5,8-dihydroxy-5,6,7,8-tetrahydro-1,4-naphthoquinone (1a, 1b) were for the first time synthesized from 5,8-dihydroxy-1,4-naphthoquinone (naphthazazine) (6) as a starting material and racemic triol (3) was first synthesized from 7. The configuration of 1a was determined by X-ray analysis.

Key words naphthoquinone; spiroacetal-bridged compound; antitumor activity

Sch 49210 (2) is a novel metabolite having antitumor and inhibitory phospholipase D activities and was isolated from a fungal culture broth by Chu et al. in 1994.¹⁾ Compound 2 contains a unique structure, ketobisepoxydecalone with a spiroacetal linkage through a naphthalene moiety. CJ-12, 372 (4) isolated by Sakemi *et al.*²⁾ was shown to possess DNA gyrase inhibition activity and is a spiroacetal compound with 1,8-naphtalenediol (5) as compound 2. Recently, investigations of analogous compounds of 2 and 4 have been reported and the syntheses of a series of these naturally occurring spiroacetal-bridged compouds were published.³⁻¹¹⁾ The svnthesis of bisepoxide 2 and naphthalene dimer 4 has not yet been published, however, we initially began to synthesize key compounds 1a and 3 for 2 and 4 (Chart 1). In this paper, we describe the first synthesis of *cis*- and *trans*-5,8-dihydroxy-5,6,7,8-tetrahydro-1,4-naphthoquinone (1a, 1b) by two routes, and also the first synthesis of racemic triol 3.

Results and Discussion

2,3-Dihydro-5,8-dihydroxy-1,4-naphthoquinone (7) was synthesized from naphthazazine (6) as the starting material by applying the procedure¹²⁾ developed by Pearson *et al.* Reduction of 6 by 20 eq of stannous chloride under acidic conditions gave dihydro compound 7 in 90% yield (Chart 2). Diol 7 was used in the following procedure without purification because 7 is unstable to air-oxidation and returns to starting material 6 easily. Diol 7 was then reduced by treatment with large excess (24 eq) of NaBH₄ in the presence of a catalytic amount of CeCl₃¹³⁻¹⁵⁾ in tetrahydrofuran (THF) at room temperature to afford a mixture of **8a** and **8b**. Oxidation of a mixture of **8a** and **8b** using ceric ammonium nitrate (CAN)¹⁶⁻¹⁸⁾ as an oxidant in acetonitrile gave a mixture of



Fig. 1. ORTEP Views of 1a

* To whom correspondence should be addressed. e-mail: arimas@pharm.kitasato-u.ac.jp

1a (*cis*) and **1b** (*trans*).¹⁹ The mixture was separated by column chromatography to give crystals **1a** and oil **1b** in 34 and 50% yields, respectively (Chart 2). The stereostructures of **1a** and **1b** were decided as follows. The determination whether **1a** and **1b** are the *cis* or *trans* isomer by ¹H-NMR spectra presented great difficulty because each spectrum exhibits a complicated coupling pattern. Therefore, X-ray analysis of **1a** was performed. The ORTEP view of **1a** showed a *cis* diol structure and exhibited interesting stereochemical features as shown in Fig. 1. The cyclohexane ring adopts a half-chair conformation and two carbonyl groups in quinone are above so that they are apart from each *cis* hydroxyl group. From these results, it was proved that **1a** and **1b** are correspondent to a *cis* and *trans* diol, respectively.

In the procedure shown in Chart 2, separation of **1a** and **1b** by column chromatography was difficult because their *Rf* values are very close in spite of the short process. We therefore developed another method for **1a** and **1b** as shown in Chart 3. Methylation of **6** by treatment with Ag₂O and CH₃I afforded **9** in 76% yield according to the procedure developed by Pearson and co-workers.¹²⁾ At first LiAlH₄ was used as a reducing agent, but 1,4-dihydroxy-5,8-dimetoxynaphthalene was obtained as a main compound by enolization. To avoid enolization, the selective 1,2-reduction was next performed with NaBH₄ in the presence of a catalytic amount of CeCl₃.¹³⁻¹⁵⁾ Thus, methyl ether **9** was converted to a mixture of diols **10a** and **10b** by treatment with NaBH₄ in the presence of **10a** and **10b** was used in the next reaction without separation because of their



Chart 1

© 2001 Pharmaceutical Society of Japan



Chart 2



4 eq NaBH₄. 7 <u>cat. CeCl₃</u> THF. 0 'C. 30 min 0 H 0 3 (77.0 %) Chart 4

instability. Catalytic hydrogenation of a mixture of **10a** and **10b** with PtO_2 under hydrogen, followed by purification by column chromatography afforded **11a** (*cis*) and **11b** (*trans*) in 31 and 31% yield, respectively.²⁰⁾ Oxidation of **11a** and **11b** by treatment with CAN^{16–18)} afforded **1a** and **1b** in 63 and 45% yield, respectively.

The stereostructures of **11a** and **11b** were determined by comparison of ¹H-NMR spectra of **1a** and **1b** with the spectra of these obtained by another procedure shown in Chart 2. Reduction of **7** using 4 eq of NaBH₄ in THF at 0 °C in the presence of a catalytic amount of CeCl₃ afforded stable racemic triol **3** in 77% yield. We are now going to synthesize **4** by acetalization of protected ketone derived from **3** and then coupling reaction with **5**.

In conclusion, **1a** and racemic **3** which are important synthetic intermediates for bioactive spiro ketal **2** and **4** were for the first time synthesized. The stereostructures of **1a** were precisely determined by X-ray analysis.

Experimental

Melting points were taken on a Yanagimoto hot-stage and are uncorrected. ¹H- and ¹³C-NMR were recorded on Varian VXR-300 and XL-400 spectrometers. The signals were assigned on the basis of ¹H–¹H correlation spectroscopy (COSY), distortionless enhancement by polarization transfer (DEPT), heteronuclear multiple quantum coherence (HMQC), and heteronuclear multiple bond connectivity (HMBC) experiments. Mass spectra were obtained on a JEOL JMS-DX 300 mass spectrometer (low-resolution mass spectrometry) and a JEOL JMS-AX505 HA mass spectrometer (high-resolution (HR) mass spectrometry). Flash column chromatography was performed on Silica gel 60 H (Merck). Thin-layer chromatography (TLC) was done on Silica gel 60 PF₂₅₄ (Merck).

5,8-Dihydroxy-1,2,3,4-tetrahydronaphthalene-1,4-dione (7) The synthetic method of 7 was modified for that of Pearson *et al.*¹²⁾ The suspension of 5,8-dihydroxy-1,4-naphthoquinone (**6**) (50.3 mg, 0.3 mmol) and stannous chloride (1.0 g, 5.3 mmol) in $4 \times$ HCl (10 ml) was refluxed for 75 min. The hot reaction mixture was immediately filtered through a Celite pad, and the precipitate was washed with hot water (2 ml). The filtrate and the washings were combined and extracted with CHCl₃ (30 ml×3). The CHCl₃ layer was washed with brine (2 ml), dried over Na₂SO₄ and evaporated *in vacuo* to give the crude product **7** as yellow crystals (40.5 mg, 89.7%). **7**: mp 152—157 °C (lit.¹⁴⁾ 154 °C). *Rf*=0.8 (CHCl₃: CH₃OH=50:1). ¹H-NMR (400 MHz, CDCl₃) δ : 11.92 (2H, s, 5, 8-OH), 7.25 (2H, s, 6,7-H), 3.05 (4H, s, 2,3-H₂). ¹³C-NMR (100.6 MHz, CDCl₃) δ : 201.4 (s, C-1, 4), 155.2 (s, C-5, 8), 128.5 (d, C-6, 7), 114.4 (s, C-9, 10), 36.4 (t, C-2, 3). IR (CHCl₃) cm⁻¹: 3150, 1640, 1600. HR-electron impact (EI)-MS *m/z*: 192.0429 [M]⁺ (Calcd for C₁₀H₈O₄: 192.0423).

Cis- and trans-5,8-Dihydroxy-5,6,7,8-tetrahydro-1,4-naphthoquinone (1a, 1b) from 7 To a solution of 7 (20.0 mg, 0.11 mmol) in THF (5 ml) were added CeCl₃·7H₂O (31.3 mg, 0.08 mmol) and NaBH₄ (23.8 mg, 0.63 mmol) at room temperature. After stirring for 50 min, excess NaBH₄ was quenched with H₂O (0.5 ml). The mixture was evaporated in vacuo and the residue was acidified to pH 4 with 5% aqueous HCl and extracted with AcOEt (20 ml×3). The AcOEt layer was dried over Na₂SO₄, and concentrated to half in vacuo. A solution of CAN (115.1 mg, 0.21 mmol) in CH₃CN (20 ml) was added dropwise to the solution mentioned above at 0 °C. The mixture was stirred at room temperature for 60 min, and evaporated in vacuo. The residue was extracted with CHCl₃ (20 ml×4), and washed with brine, dried over Na₂SO₄ and evaporated in vacuo. The residue was purified by preparative TLC (CHCl₃: CH₃OH=10:1) to give the mixture of 1a and 1b (20.0 mg, 93.7% from 7, 1a:1b=1:1.5), which was further purified by flash column chromatography (CHCl₃) to give **1a** as yellow crystals (6.8 mg, 33.6%) and 1b as yellow oil (10.2 mg, 50.4%). 1a: mp. 120 °C; Rf=0.50 (CHCl₂: CH₃OH=10:1). ¹H-NMR (400 MHz, CDCl₃) δ: 6.77 (2H, s, 2,3-H), 4.74 (2H, t, J=5.0 Hz, 5, 8-H), 3.19 (2H, br, 5,8-OH), 1.82-1.93, 1.97–2.08 (2H, m, each 6,7-H₂). ¹³C-NMR (100.6 MHz, CDCl₃) δ : 189.0 (s, C-1, 4), 141.8 (s, C-9, 10), 136.8 (d, C-2, 3), 63.3 (d, C-5, 8), 25.5 (t, C-6, 7). IR (CHCl₃) cm⁻¹: 3550, 2950, 1640, 1600. HR-FAB-MS *m/z*: 194.0579 $[M]^+$ (Calcd for C₁₀H₁₀O₄: 194.0579). **1b**: *Rf*=0.51 (CHCl₃: CH₃OH=10: 1). ¹H-NMR (400 MHz, CDCl₃) δ: 6.78 (2H, s, 2,3-H), 4.79 (2H, br, 5,8-H), 2.98 (2H, br, 5,8-OH), 2.13, 1.80 (2H, m, each 6,7-H₂). ¹³C-NMR (100.6 MHz, CDCl₃) δ: 189.0 (s, C-1, 4), 141.4 (s, C-9, 10), 136.7 (d, C-2, 3), 62.3 (d, C-5, 8), 25.3 (t, C-6, 7). IR (CHCl₃) cm⁻¹: 3550, 2950, 1640, 1600. HR-FAB-MS m/z: 217.0421 [M+Na]⁺ (Calcd for C₁₀H₁₀O₄Na: 217.0476).

5,8-Dimethoxy-1,4-naphthoquinone (9) The synthetic method of **9** was modified for that of Pearson *et al.*¹²⁾ Silver oxide (500.0 mg, 2.2 mmol) and methyl iodide (2.0 ml, 32.1 mmol) were added to a solution of 5,8-dihydroxy-1,4-naphthoquinone (**6**) (545.6 mg, 2.9 mmol) in CHCl₃ (40.0 ml), and the mixture was refluxed at $60-65 \,^{\circ}$ C for 5 d. Silver oxide (500.0 mg, 2.2 mmol×4) and methyl iodide (2.0 ml, 32.1 mmol×9) were added repeatedly until the reaction was completed during 5 d. Then the mixture was filtered through a Celite pad, and the solid was washed with CHCl₃ (20.0 ml). The filtrate and the washings were combined and evaporated *in vacuo*. The residue was purified by preparative TLC (CHCl₃ : CH₃OH=50:1) to give **9**

as orange crystals (475.1 mg, 75.9%). **9**: mp. 151—155 °C (lit.¹²⁾ 155 °C); *Rf* = 0.34 (CHCl₃ : CH₃OH=50 : 1). ¹H-NMR (400 MHz, CDCl₃) δ : 7.32 (2H, s, 6,7-H), 6.77 (2H, s, 2,3-H), 3.95 (6H, s, 5,8-OCH₃). ¹³C-NMR (100.6 MHz, CDCl₃) δ : 184.8 (s, C-1, 4), 153.7 (s, C-5, 8), 138.3 (d, C-2, 3), 120.4 (d, C-6, 7), 119.7 (s, C-9, 10), 56.9 (q, 5,8-OCH₃). IR (CHCl₃) cm⁻¹: 1640. HR-FAB-MS *m/z*: 220.0737 [M+2H]⁺ (Calcd for C₁₂H₁₂O₄: 220.0735).

Cis- and *trans-5,8-Dimethooxy-1,2,3,4-tetrahydronaphthalene-1,4-diol* (11a, 11b) To a solution of 9 (50.0 mg, 0.23 mmol) in CH₃OH (8 ml) were added CeCl₃· 7H₂O (68.6 mg, 0.18 mmol) and NaBH₄ (34.8 mg, 0.92 mmol) at room temperature. After stirring for 30 min, excess NaBH₄ was quenched by H₂O (5 ml). The mixture was evaporated *in vacuo* and was further added H₂O (5 ml) and extracted with CHCl₃ (30 ml×3). The CHCl₃ layer was washed with brine (5 ml×2), dried over Na₂SO₄, and concentrated *in vacuo* to give the crude products (the mixture of **10a** and **10b**) (55.0 mg).

A solution of the crude products (the mixture of 10a and 10b) in EtOH (3 ml) was added to a suspension of PtO₂ (10 mg) in EtOH (1 ml) and hydrogenated for 25 min. After the reaction was completed, PtO2 was removed by filtration. The filtrate was evaporated in vacuo to give the crude compounds of 11a and 11b (60.9 mg). These compounds were purified by column chromatography (hexane: AcOEt=2:1) to give 11a as orange oil (16.1 mg, 31.3%) and 11b as orange crystals (15.8 mg, 30.8%). 11a: Rf=0.21 (benzene: AcOEt=1:1). ¹H-NMR (400 MHz, CDCl₂) δ : 6.78 (2H, s, 6,7-H), 4.97 (2H, t, J=5.5 Hz, 1,4-H), 3.85 (6H, s, 5,8-OCH₃), 3.46 (2H, br, 1,4-OH), 2.03-2.13, 1.86-1.96 (2H, m, each 2,3-H₂). ¹³C-NMR (100.6 MHz, CDCl₃) *δ*: 151.9 (s, C-5, 8), 128.9 (s, C-9, 10), 109.5 (d, C-6, 7), 64.5 (d, C-1, 4), 55.8 (q, 5, 8-OCH₃), 26.3 (t, C-2, 3). IR (CHCl₃) cm⁻¹: 3550, 2900, 1600. HR-FAB-MS m/z: 224.1042 [M]⁺ (Calcd for C₁₂H₁₆O₄: 224.1049). 11b: mp. 113—114 °C; *Rf*=0.33 (benzene: AcOEt=1:1). ¹H-NMR (400 MHz, CDCl₃) δ: 6.79 (2H, s, 6, 7-H), 5.02 (2H, t, J=2.0 Hz, 1, 4-H), 3.85 (6H, s, 5,8-OCH₃), 2.83 (2H, br, 1,4-OH), 2.12-2.18, 1.86-1.94 (2H, m, each 2,3-H₂). ¹³C-NMR (100.6 MHz, CDCl₃) δ: 151.7 (s, C-5, 8), 128.1 (s, C-9, 10), 109.6 (d, C-6, 7), 62.6 (d, C-1, 4), 55.8 (q, 5,8-OCH₃), 24.9 (t, C-2, 3). IR (CHCl₃) cm⁻¹: 3550, 2900, 1600. HR-FAB-MS m/z: 224.1042 [M]⁺ (Calcd for C₁₂H₁₆O₄: 224.1049).

1a from 11a A solution of CAN (97.6 mg, 0.18 mmol) in CH₃CN (2.4 ml) was added dropwise to a solution of **11a** (20.3 mg, 0.09mmol) in CH₃CN (1.4 ml) at 0 °C. The mixture was stirred at room temperature for 30 min, and was evaporated *in vacuo*. Brine (3 ml) was added to the residue, and was extracted with CHCl₃ (20 ml×4). The CHCl₃ layer was dried over Na₂SO₄ and evaporated *in vacuo*. The residue was purified by preparative TLC (CHCl₃: CH₃OH=50:1) to give **1a** as yellow crystals (11.1 mg, 63.1%). **1a** was identical with **1a** obtained from 7 described above by comparison of the ¹H-NMR spectra.

1b from 11b A solution of CAN (142.5 mg, 0.26 mmol) in CH₃CN (3.5 ml) was added dropwise to a solution of 11b (29.2 mg, 0.13mmol) in CH₃CN (2.0 ml) at 0 °C. The mixture was stirred at room temperature for 30 min, and was evaporated *in vacuo*. Brine (3 ml) was added to the residue, and was extracted with CHCl₃ (30 ml×3). The CHCl₃ layer was dried over Na₂SO₄ and evaporated *in vacuo*. The residue was purified by preparative TLC (CHCl₃:CH₃OH=50:1) to give 1b as yellow oil (11.4 mg, 45.2%). 1b was identical with 1b obtained from 7 described above by comparison of the ¹H-NMR spectra.

4,5,8-Trihydroxy-1,2,3,4-tetrahydronaphthalene-1-one (3) To a solution of 7 (200.0 mg, 1.04 mmol) in THF (12 ml) were added CeCl₃·7H₂O (155.0 mg, 0.42 mmol) and NaBH₄ (39.3 mg, 1.04 mmol) at 0 °C. After stirring for 30 min, the reaction was quenched by H₂O (5.0 ml). The mixture was evaporated *in vacuo* and the residue was acidified to pH3 with 10% aqueous HCl and extracted with AcOEt (50 ml×2). The AcOEt layer was dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by preparative TLC (CHCl₃: CH₃OH=10:1) to give **3** as yellow oil (155.4 mg, 77.0%). **3**: *Rf*=0.41 (CHCl₃: CH₃OH=10:1). ¹H-NMR (400 MHz, CDCl₃) &: 12.02 (1H, s, 8-OH), 7.77 (1H, br, 5-OH), 7.07 (1H, d, *J*=9.0 Hz, 6-H), 6.85 (1H, d, *J*=9.0 Hz, 7-H), 5.27 (1H, dd, *J*=5.5, 10.0 Hz, 4-H), 2.78—2.90, 2.56—2.70 (1H, m, each 2-H), 2.37—2.48, 2.11—2.26 (1H, m, each 3-H), 1.70 (1H, br, 4-OH). ¹³C-NMR (100.6 MHz, CDCl₃) &: 203.4 (s, C-1),

156.5 (s, C-8), 147.3 (s, C-5), 126.6 (d, C-6), (s, C-10), 118.4 (d, C-7), 114.8 (s, C-9), 67.2 (d, C-4), 35.4 (t, C-2), 31.4 (t, C-3). IR (CHCl₃) cm⁻¹: 1640, 1600. HR-EI-MS *m/z*: 194.0576 [M]⁺ (Calcd for $C_{10}H_{10}O_4$: 194.0579).

X-Ray Crystallographic Analysis of 1a Compound **1a** was crystallized from AcOEt to give a red prismatic crystal of $C_{10}H_{10}O_4$ having approximate dimensions of $0.400 \times 0.400 \times 0.300$ mm, which was mounted on a glass fiber.

Crystal Data for **1a**: Formula $C_{10}H_{10}O_4$, fw=194.19; triclinic, space group P1(#2), a=9.826(3) Å, b=12.380(2) Å, c=8.648(2)Å, $\alpha=106.43(2)^\circ$, $\beta=111.54(2)^\circ$, $\gamma=68.10(2)^\circ$, V=894.9(4)Å³; Z=4, $D_{calc}=1.441$ g/cm³. R=0.088, $R_w=0.096$ for 1984 observed reflections with $I>5.00\sigma(I)$. All measurements were made on a Rigaku AFC5S diffractometer with graphite monochromated CuK α radiation ($\lambda=1.54178$ Å) and a 12 KW rotating anode generator. Cell constants and an orientation matrix for date collection were obtained from a least-squares. The data were collected at a temperature of 23 ± 1 °C using the $\omega-2\theta$ scan technique to a maximum 2θ value of 135.1°, and were corrected for Lorentz and polarization effects. The structure was solved by direct methods using MITHRIL.²¹⁾ The non-hydrogen atoms were refined anisotropically. All calculations were performed using the TEXSAN²²⁾ crystallographic software package of the Molecular Structure Corporation.

Reference and Notes

- Chu M., Truumees I., Patel M. G., Gullo V. P., Blood C., King I., Pai J.-K., Puar M. S., *Tetrahedron Lett.*, **35**, 1343–1346 (1994).
- Sakemi S., Inagaki T., Kaneda K., Hirai H., Iwata E., Sakakibara T., Yamauchi Y., Norcia M., Wondrack L. M., Sutcliffe J. A., Kojima N., J. Antibiot., 48, 134–142 (1995).
- Barett A. G. M., Hamprecht D., Meyer T., Chem. Commun., 1998, 809–810.
- Ragot J. P., Alcaraz M.-L., Taylor R. J. K., *Tetrahedron Lett*, 39, 4921–4924 (1998).
- 5) Wipf P., Jung J.-K., J. Org. Chem., 63, 3530-3531 (1998).
- Wipf P., Jung J.-K., Rodríguez S., Lazo J. S., *Tetrahedron*, 57, 283– 296 (2001).
- 7) Chi S., Heachcock C. H., Org. Lett., 1, 3–5 (1999).
- 8) Wipf P., Jung J.-K., J. Org. Chem., 64, 1092–1093 (1999).
- 9) Wipf P., Jung J.-K., J. Org. Chem., 65, 6319-6337 (2000).
- Ragot J. P., Steeneck C., Alcaraz M.-L., Taylor R. J. K., J. Chem. Soc., Perkin Trans. 1, 1999, 1073–1082.
- Ragot J. P., Prime M. E., Archibald S. J., Taylor R. J. K., Org. Lett., 2, 1613—1616 (2000).
- 12) Pearson M. S., Jensky B. J., Greer F. X., Hagstrom J. P., Wells N. M., J. Org. Chem., 43, 4617–4622 (1978).
- 13) Luche J.-L., Rodriguez-Hahn L., Crabbé P., J. Chem. Soc., Chem. Commun., 1978, 601-602.
- 14) Gemal A. L., Luche J.-L., J. Am. Chem. Soc., 103, 5454-5459 (1981).
- 15) Marchand A. P., LaRoe W. D., Sharma G. V. M., Suri S. C., Reddy D. S., J. Org. Chem., 51, 1622—1625 (1986).
- 16) Broadhurst M. J., Hassall C. H., Thomas G. J., J. Chem. Soc., Chem. Commun., 1982, 158—160.
- 17) Takeuchi Y., Sudani M., Yoshii E., J. Org. Chem., 48, 4151-4152 (1983).
- Kawasaki M., Matsuda F., Terashima S., *Tetrahedron*, 44, 5713—5725 (1988).
- 19) The NaBH₄-CeCl₃ reduction of 7 was examined at several temperatures and the ratio of the yields of 1a and 1b from 7 at 80 °C, room temperature and -70 °C exhibited 1: 1.5 (82%), 1: 1.5 (84%) and 1: 2 (94%), respectively. (Total yield is described in parenthesis.)
- 20) The NaBH₄-CeCl₃ reduction of **9** was examined at several temperatures and the yields of **11a** and **11b** from **9** at 75 °C and -50 °C exhibited 26 and 33%, and 27 and 42%, respectively.
- 21) Gilmore C. J., J. Appl. Cryst., 17, 42-46 (1984).
- TEXSAN-TEXRAY Structure Analysis Package, Molecular Structure Corporation, 1985.